Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neogenomics Inc (NEO)

Neogenomics Inc (NEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 933,348
  • Shares Outstanding, K 129,812
  • Annual Sales, $ 727,330 K
  • Annual Income, $ -108,030 K
  • EBIT $ -116 M
  • EBITDA $ -46 M
  • 60-Month Beta 1.62
  • Price/Sales 1.38
  • Price/Cash Flow 23.16
  • Price/Book 1.20

Options Overview Details

View History
  • Implied Volatility 160.38% (-39.78%)
  • Historical Volatility 50.84%
  • IV Percentile 94%
  • IV Rank 43.41%
  • IV High 315.47% on 03/13/26
  • IV Low 41.44% on 08/15/25
  • Expected Move (DTE 18) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 10,689
  • Open Int (30-Day) 9,589
  • Expected Range 7.20 to 7.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.08
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.07 +1.91%
on 03/30/26
9.82 -26.68%
on 03/02/26
-2.63 (-26.75%)
since 02/27/26
3-Month
7.07 +1.91%
on 03/30/26
13.74 -47.60%
on 01/12/26
-5.08 (-41.37%)
since 12/26/25
52-Week
4.72 +52.54%
on 08/01/25
13.74 -47.60%
on 01/12/26
-2.42 (-25.16%)
since 03/28/25

Most Recent Stories

More News
2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

DRS : 43.25 (-3.55%)
NEO : 7.20 (+0.14%)
BWXT : 191.59 (-5.43%)
3 Russell 2000 Stocks We Approach with Caution

3 Russell 2000 Stocks We Approach with Caution

RUSHA : 64.97 (-1.68%)
NEO : 7.20 (+0.14%)
DBRG : 15.40 (+0.13%)
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

NTRA : 186.84 (+2.29%)
NEO : 7.20 (+0.14%)
AMPH : 19.22 (+1.10%)
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the PanTracer™ LBx test has received coverage from the Centers...

NEO : 7.20 (+0.14%)
3 Reasons to Avoid NEO and 1 Stock to Buy Instead

3 Reasons to Avoid NEO and 1 Stock to Buy Instead

NEO : 7.20 (+0.14%)
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

We estimate that MRD represents a $20+ billion addressable market, growing at 30% annually, which we believe is less than 10% penetrated

NEO : 7.20 (+0.14%)
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call

NEO : 7.20 (+0.14%)
Why NeoGenomics (NEO) Shares Are Falling Today

Why NeoGenomics (NEO) Shares Are Falling Today

NEO : 7.20 (+0.14%)
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:...

NEO : 7.20 (+0.14%)
NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO Q4 Deep Dive: Product Mix Shift and Guidance Weigh on Outlook

NEO : 7.20 (+0.14%)

Business Summary

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology...

See More

Key Turning Points

3rd Resistance Point 7.56
2nd Resistance Point 7.44
1st Resistance Point 7.32
Last Price 7.20
1st Support Level 7.07
2nd Support Level 6.95
3rd Support Level 6.83

See More

52-Week High 13.74
Fibonacci 61.8% 10.29
Fibonacci 50% 9.23
Fibonacci 38.2% 8.17
Last Price 7.20
52-Week Low 4.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.